RxDoctor Payments Data

Stephanie McAuley

Family · Southern Pines, NCNPI 1982254751

Payments from drug & device makers

$3,510in general payments, 2019–2025

Across 127 payments — averaging $27.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$458
  • AbbVie$376
  • Novo Nordisk$290
  • Daiichi Sankyo Inc.$175
  • Organon$121
  • plus $904 from 21 others

What the payments were for

  • Travel & lodging$79123%
  • Food & beverage$2,61875%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,510 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$17,740
Medicare patients
139
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated17$7,399
MyrbetriqMirabegron12$6,173
Estradiol142$5,195
Estradiol (Once Weekly)Estradiol32$1,963
Estradiol (Twice Weekly)Estradiol22$1,248
ProgesteroneProgesterone, Micronized23$937
Medroxyprogesterone Acetate20$602
Clobetasol Propionate13$412
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip20$372
Escitalopram Oxalate12$295
Nystatin23$271
Drospirenone-Ethinyl EstradiolEthinyl Estradiol/Drospirenone15$259
Ibandronate Sodium12$157
Alendronate Sodium16$119
Fluconazole23$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$52$7,39917 claims
Astellas Pharma US IncMyrbetriq$458$6,17312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →